April 17, 2024
Global Autoimmune Polyglandular Syndrome Type 1 Market

Global Autoimmune Polyglandular Syndrome Type 1 Market Trends by Genetic Disorders

Autoimmune Polyglandular Syndrome Type 1 (APS1) or Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED) is a rare, chronic disorder that results from mutations in the AIRE gene. It is characterized by chronic mucocutaneous candidiasis, hypoparathyroidism, and Addison’s disease. The condition develops due to failures in the immune system that normally protect the body from infection and disease. These failures cause the immune system to attack and destroy healthy tissues and organs. The complex interplay between genetic and environmental factors results in this group of autoimmune disorders affecting multiple endocrine and non-endocrine organs. The Global Autoimmune Polyglandular Syndrome Type 1 Market is estimated to be valued at US$ 257.0 million in 2024 and is expected to exhibit a CAGR of 3.1% over the forecast period from 2024 to 2030.

Key Takeaways

Key players operating in the Global Autoimmune Polyglandular Syndrome Type 1 Market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S. With rising prevalence and lack of cure, companies are investing heavily in research and development of new drugs and therapies.

The growing incidences of genetic disorders as well as increasing awareness about rare diseases is driving the demand for Autoimmune Polyglandular Syndrome Type 1 treatment. According to the European Society for Immunodeficiencies, it is estimated that 1 in 2000 people in Finland and other Nordic countries have Autoimmune Polyglandular Syndrome Type 1.

Globally, companies are expanding their presence across different geographies to tap the market potential. For instance, in September 2022, Zydus Lifesciences received approval to market Everolimus tablets in the USA for the treatment of Autoimmune Polyglandular Syndrome Type 1 in adults and pediatric patients.

Market Key Trends

The key trend in the Global Autoimmune Polyglandular Syndrome Type 1 Market is the increasing research on gene therapies. Since APS1 is primarily caused due to mutations in the AIRE gene located on chromosome 21, scientists are exploring ways to replace or modify this defective gene as a potential cure. Companies like Amicus Therapeutics are conducting research to develop one-time curative gene therapies using adeno-associated viral vectors to transduce the correct version of the AIRE gene. If successful, gene therapies promise lifelong correction for APS1 without the need for lifelong immunosuppressive drugs currently used to manage symptoms. This is expected to significantly impact the treatment landscape in the coming years.

Porter’s Analysis
Threat of new entrants: Low as high R&D costs and intellectual property rights hamper new entrants in this market.
Bargaining power of buyers: Moderate as there are few treatment options for autoimmune polyglandular syndrome type 1 and buyers have to rely on few major manufacturers.
Bargaining power of suppliers: Low due to availability of substitute raw materials.
Threat of new substitutes: Low as there are limited treatment options and substitutes available for autoimmune polyglandular syndrome type 1.
Competitive rivalry: High among existing players to gain higher market share as it is an oligopolistic market with few major brands dominating the market.

Geographical Regions
In terms of value, North America region accounted for the major share in global autoimmune polyglandular syndrome type 1 market in 2024 and is expected to continue its dominance during the forecast period. This is attributed to developed healthcare infrastructure, high diagnosis rates, and strong presence of key market players in the region.

Asia Pacific region is considered to be the fastest growing market for autoimmune polyglandular syndrome type 1 over the forecast period from 2024 to 2030. Rising healthcare awareness, improving healthcare infrastructure, increasing per capita income, and presence of emerging economies like India and China in the region provide lucrative opportunities for the market players.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it